ArticleVaccines2024

Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia.

Sharifah Shakinah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.